All Comparisons
Hexarelin vs Tesamorelin
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Hexarelin: CTesamorelin: A
| Attribute | Hexarelin | Tesamorelin |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Evidence Rating | C — Phase I–II Clinical Trials | A — FDA Approved |
| Clinical Status | Phase II completed. Development discontinued due to tolerance/desensitization concerns. | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Mechanism | Hexarelin binds to and activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus through a triple mechanism: direct stimulation of pituitary somatotroph cells to release stored GH, stimulation of hypothalamic GHRH-releasing neurons, and suppression of som... | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. This increases IGF-1 and IGFBP-3 levels, leading to increased lipolysis and redu... |
| Half-Life | ~70 minutes | ~26–38 minutes |
| Bioavailability | — | — |
| Molecular Weight | ~887 g/mol | ~5135.9 g/mol |
| WADA Status | Prohibited | Prohibited |
| Research Half-Life | ~70 minutes | ~26–38 minutes |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Development discontinued. Research chemical only. | FDA-approved: Egrifta SV (Oct 2019) and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Prescription only. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Hexarelin | Tesamorelin |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 140703-51-1 | 218949-48-5 |
| Molecular Formula | N/A | C₂₂₃H₃₇₀N₇₂O₆₉S |
| Available Formats | 5mg | 10mg, 20mg, 10mg |
| Batch COAs Published | — | 1 on file |
| Stock Status | Out of stock | In stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.